Figure 2.
Kaplan–Meyer analysis of time to progression (TTP). Among 62 patients, 31 received sorafenib and 31 received placebo. The median TTP was 9.2 months in the sorafenib group and 4.9 months in the placebo group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.